The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia.
Talpaz
M
M
Department of Bioimmunotherapy, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Kantarjian
H M
HM
O'Brien
S
S
Kurzrock
R
R
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002173:Cancer Care Facilities; D002986:Clinical Trials as Topic; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D013781:Texas; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D016898:Interferon-alpha